Tumor Imaging

DIAGNOSTIC_TEST3 trials

Sponsors

HonorHealth Research Institute, Merck Sharp & Dohme LLC, University of California, San Francisco

Conditions

Carcinoma, Non-Small-Cell LungMantle Cell LymphomaMetastatic Pancreatic Cancer

Phase 2

Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine

TerminatedNCT03714555

HonorHealth Research InstituteMetastatic Pancreatic Cancer

Start: 2019-10-17End: 2020-07-29Updated: 2023-10-18

Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

RecruitingNCT06252675

University of California, San FranciscoMantle Cell Lymphoma

Start: 2024-06-11End: 2028-07-31Target: 30Updated: 2025-10-22

Unknown Phase

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

RecruitingNCT04165798

Merck Sharp & Dohme LLCCarcinoma, Non-Small-Cell Lung

Start: 2019-12-19End: 2032-02-13Target: 1065Updated: 2026-04-02

Related Papers

Combination of Glofitamab with Pirtobrutinib in BTK Inhibitor (BTKi)-Naive or Btki-Intolerant Patients with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL): A Multicenter Phase 2 Study of the University of California Hematologic Malignancies Consortium

Blood2024-11-05

Abstract CT249: Results from KEYMAKER-U01 substudy 3: a phase 2 umbrella study of pembrolizumab plus investigational agents in patients with non-small-cell lung cancer (NSCLC) previously treated with anti-PD-(L)1 therapy

Cancer Research2024-04-051 citations